Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis

被引:27
|
作者
Lipton, RB
Pascual, J
Goadsby, PJ
Massiou, H
McCarroll, KA
Vandormael, K
Jiang, KH
Lines, CR
机构
[1] Innovat Med Res Inc, Stamford, CT 06905 USA
[2] Albert Einstein Coll Med, Bronx, NY USA
[3] Univ Hosp Marques de Valdecilla, Santander, Spain
[4] Neurol Inst, London, England
[5] Hop Lariboisiere, F-75475 Paris, France
[6] Merck Res Labs, West Point, PA USA
来源
HEADACHE | 2001年 / 41卷 / 08期
关键词
rizatriptan; sumatriptan; naratriptan; zolmitriptan; 5-HT1B/1D receptor agonists; migraine; nausea; baseline; emergent;
D O I
10.1046/j.1526-4610.2001.01139.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack. Methods.-Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were retrospectively analyzed. Migraine was diagnosed according to International Headache Society criteria. Presence or absence of nausea was recorded at baseline and at 0.5, 1, 1.5, and 2 hours after dosing. The end points analyzed were relief of nausea in those who had it at baseline and emergence of nausea in those who were free of it at baseline. Treatments were compared using odds ratios estimated from logistic regression models at 2 hours, and averaged odds ratios for the first 2 hours posttreatment. Results.-Approximately 60% of patients in each treatment group had nausea at baseline. In those patients with nausea at baseline, significantly more patients treated with rizatriptan 10 mg were free of nausea at 2 hours compared with sumatriptan 100 mg (66% versus 58%, P=.043), sumatriptan 50 mg (68% versus 57%, P=.010), sumatriptan 25 mg (68% versus 59%, P=.017), and naratriptan 2.5 mg (59% versus 45%, P=.014). Averaging over the four posttreatment time points in the first 2 hours, significantly more patients treated with rizatriptan 10 mg were free of nausea compared with sumatriptan 100 mg (P=.004), sumatriptan 50 mg (P=.001), and naratriptan 2.5 mg (P=.015). No significant differences in nausea relief were seen between rizatriptan 10 mg and zolmitriptan 2.5 mg, either at 2 hours (65% versus 61%, P=.210) or over the first 2 hours (P=.781). Rates of treatment-emergent nausea at 2 hours ranged from 11% to 18% with placebo, from 5% to 13% with rizatriptan 10 mg, and from 10% to 20% with other comparator triptans. Conclusions.-Oral rizatriptan 10 mg was more effective than oral sumatriptan and naratriptan at eliminating nausea within 2 hours in patients who had it at baseline. Rates of emergent nausea in patients who were free of it at baseline were low, and no consistent differences were observed between active treatments.
引用
收藏
页码:754 / 763
页数:10
相关论文
共 50 条
  • [41] Post Hoc Analysis of PROGRESS: Evaluating the Safety of Atogepant in Participants With Chronic Migraine and Cardiovascular Risk Factors
    Best, Patricia
    Harriott, Andrea
    Monteith, Teshamae
    Tassorelli, Cristina
    Nahas, Stephanie
    Liu, Yingyi
    Dabruzzo, Brett
    Ferreira, Rosa De Abreu
    Smith, Jonathan H.
    NEUROLOGY, 2023, 100 (17)
  • [42] Post hoc analysis of progress: Evaluating the safety of atogepant in participants with chronic migraine and cardiovascular risk factors
    Best, Patricia
    Harriott, Andrea
    Monteith, Teshamae
    Tassorelli, Cristina
    Nahas, Stephanie
    Davidovic, Goran
    Liu, Yingyi
    Dabruzzo, Brett
    Ferreira, Rosa De Abreu
    Smith, Jonathan
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [43] Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies
    G Allais
    V Tullo
    S Omboni
    C Benedetto
    G Sances
    D Zava
    MD Ferrari
    G Bussone
    The Journal of Headache and Pain, 2013, 14
  • [44] Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis
    Romera, Irene
    Perez, Victor
    Ciudad, Antonio
    Caballero, Luis
    Roca, Miguel
    Polavieja, Pepa
    Gilaberte, Inmaculada
    BMC PSYCHIATRY, 2013, 13
  • [45] Efficacy of cariprazine in patients with bipolar i mania by baseline symptom severity: a pooled, post hoc analysis
    Yatham, L.
    Earley, W.
    Cheng-Tao, C.
    Barabassy, A.
    BIPOLAR DISORDERS, 2017, 19 : 149 - 149
  • [46] Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study
    Ferguson, Gary T.
    Skarby, Tor
    Nordenmark, Lars H.
    Lamarca, Rosa
    Aksomaityte, Audrone
    Lythgoe, Dan
    Gilbert, Ileen
    Trudo, Frank
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 3123 - 3134
  • [47] Rescue Medication Use as an Indicator of Symptom Burden in Patients with COPD: A Post Hoc Analysis of the EMAX Trial
    Kerwin, E. M.
    Bjermer, L.
    Maltais, F.
    Boucot, I.
    Naya, I.
    Tombs, L.
    Jones, P.
    Compton, C.
    Lipson, D. A.
    Vogelmeier, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [48] Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis
    Irene Romera
    Víctor Pérez
    Antonio Ciudad
    Luis Caballero
    Miguel Roca
    Pepa Polavieja
    Inmaculada Gilaberte
    BMC Psychiatry, 13
  • [49] Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies
    Allais, G.
    Tullo, V.
    Omboni, S.
    Benedetto, C.
    Sances, G.
    Zava, D.
    Ferrari, M. D.
    Bussone, G.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [50] A POST HOC ANALYSIS OF THE EFFECT OF BREXPIPRAZOLE ON PATIENT ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA
    Ismail, Z.
    Pedersen, A. M.
    Thase, M. E.
    Meehan, S. R.
    Weiss, C.
    Larsen, K. G.
    Chen, D.
    Nylander, A. G.
    Baker, R. A.
    McIntyre, R. S.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (1_SUPPL): : 241 - 242